tiprankstipranks
Charles River Laboratories Intl (CH:RV6)
NYSE:RV6
Switzerland Market
RV6
Charles River Labs
RESEARCH TOOLSreports

Charles River Labs (RV6) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

RV6 Analyst Ratings

Strong Buy
12Ratings
Strong Buy
10 Buy
2 Hold
0 Sell
Based on 12 analysts giving stock ratings to
Charles
River Labs
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

RV6 Stock 12 Month Forecast

Average Price Target

$166.40
Based on 12 Wall Street analysts offering 12 month price targets for Charles River Labs in the last 3 months. The average price target is $166.40 with a high forecast of $187.64 and a low forecast of $127.75. The average price target represents a ― change from the last price of ―.
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
Highest Price Target$187.64Average Price Target$166.40Lowest Price Target$127.75
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on CH:RV6
Kallum Titchmarsh
Morgan Stanley
Morgan Stanley
CHF175.66→CHF147.71
Buy
―
Upgraded
06/18/26
Charles River upgraded to Overweight from Equal Weight at Morgan StanleyCharles River upgraded to Overweight from Equal Weight at Morgan Stanley
Barclays Analyst forecast on CH:RV6
Luke Sergott
Barclays
Barclays
CHF175.66
Buy
―
Reiterated
06/08/26
Analysts Offer Insights on Healthcare Companies: Charles River Labs (NYSE: CRL), Incyte (NASDAQ: INCY) and Pfizer (NYSE: PFE)
Bank of America Securities Analyst forecast on CH:RV6
Michael Ryskin
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
06/05/26
Analysts Are Bullish on Top Healthcare Stocks: Charles River Labs (CRL), TransMedics Group (TMDX)
TD Cowen Analyst forecast on CH:RV6
Charles Rhyee
TD Cowen
TD Cowen
CHF187.64
Buy
―
Reiterated
06/04/26
We reiterate our Buy rating
RBC Capital Analyst forecast on CH:RV6
Ryan Halsted
RBC Capital
RBC Capital
CHF171.67
Buy
―
Reiterated
06/04/26
RBC Capital Keeps Their Buy Rating on Charles River Labs (CRL)
William Blair Analyst forecast on CH:RV6
Max Smock
William Blair
William Blair
―
Buy
―
Reiterated
06/02/26
Max Smock Reiterates Buy on Charles River Laboratories, Citing Achievable 2026 Targets and Margin Expansion Upside
CLSA Analyst forecast on CH:RV6
Michael Luo CFA
CLSA
CLSA
CHF133.34→CHF174.86
Buy
―
Upgraded
05/29/26
Charles River upgraded to Outperform from Hold at CLSACharles River upgraded to Outperform from Hold at CLSA
Jefferies Analyst forecast on CH:RV6
David Windley
Jefferies
Jefferies
CHF179.65
Buy
―
Reiterated
05/08/26
Analysts Offer Insights on Healthcare Companies: Plus Therapeutics (NASDAQ: PSTV) and Charles River Labs (NYSE: CRL)
Mizuho Securities Analyst forecast on CH:RV6
Ann Hynes
Mizuho Securities
Mizuho Securities
CHF139.73→CHF153.3
Hold
―
Reiterated
05/08/26
Charles River price target raised to $192 from $175 at MizuhoCharles River price target raised to $192 from $175 at Mizuho
Robert W. Baird Analyst forecast on CH:RV6
Eric Coldwell
Robert W. Baird
Robert W. Baird
CHF159.69→CHF170.07
Buy
―
Reiterated
05/08/26
Charles River price target raised to $213 from $200 at BairdCharles River price target raised to $213 from $200 at Baird
Evercore ISI Analyst forecast on CH:RV6
Elizabeth Anderson CFA
Evercore ISI
Evercore ISI
CHF159.69→CHF175.66
Buy
―
Reiterated
05/08/26
Charles River price target raised to $220 from $200 at Evercore ISICharles River price target raised to $220 from $200 at Evercore ISI
J.P. Morgan Analyst forecast on CH:RV6
Casey Woodring
J.P. Morgan
J.P. Morgan
CHF131.75→CHF127.75
Hold
―
Assigned
04/13/26
Charles River price target lowered to $160 from $165 at JPMorganCharles River price target lowered to $160 from $165 at JPMorgan
Citi Analyst forecast on CH:RV6
Patrick B Donnelly
Citi
Citi
CHF211.59
Buy
―
Reiterated
01/15/26
Analysts Offer Insights on Healthcare Companies: Charles River Labs (NYSE: CRL) and Molina Healthcare (NYSE: MOH)
Argus Research Analyst forecast on CH:RV6
David Toung
Argus Research
Argus Research
CHF159.69
Buy
―
Upgraded
11/17/25
Charles River upgraded to Buy from Hold at ArgusCharles River upgraded to Buy from Hold at Argus
Deutsche Bank Analyst forecast on CH:RV6
Justin Bowers
Deutsche Bank
Deutsche Bank
CHF143.72→CHF147.71
Buy
―
Reiterated
08/07/25
Deutsche Bank Keeps Their Buy Rating on Charles River Labs (CRL)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on CH:RV6
Kallum Titchmarsh
Morgan Stanley
Morgan Stanley
CHF175.66→CHF147.71
Buy
―
Upgraded
06/18/26
Charles River upgraded to Overweight from Equal Weight at Morgan StanleyCharles River upgraded to Overweight from Equal Weight at Morgan Stanley
Barclays Analyst forecast on CH:RV6
Luke Sergott
Barclays
Barclays
CHF175.66
Buy
―
Reiterated
06/08/26
Analysts Offer Insights on Healthcare Companies: Charles River Labs (NYSE: CRL), Incyte (NASDAQ: INCY) and Pfizer (NYSE: PFE)
Bank of America Securities Analyst forecast on CH:RV6
Michael Ryskin
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
06/05/26
Analysts Are Bullish on Top Healthcare Stocks: Charles River Labs (CRL), TransMedics Group (TMDX)
TD Cowen Analyst forecast on CH:RV6
Charles Rhyee
TD Cowen
TD Cowen
CHF187.64
Buy
―
Reiterated
06/04/26
We reiterate our Buy rating
RBC Capital Analyst forecast on CH:RV6
Ryan Halsted
RBC Capital
RBC Capital
CHF171.67
Buy
―
Reiterated
06/04/26
RBC Capital Keeps Their Buy Rating on Charles River Labs (CRL)
William Blair Analyst forecast on CH:RV6
Max Smock
William Blair
William Blair
―
Buy
―
Reiterated
06/02/26
Max Smock Reiterates Buy on Charles River Laboratories, Citing Achievable 2026 Targets and Margin Expansion Upside
CLSA Analyst forecast on CH:RV6
Michael Luo CFA
CLSA
CLSA
CHF133.34→CHF174.86
Buy
―
Upgraded
05/29/26
Charles River upgraded to Outperform from Hold at CLSACharles River upgraded to Outperform from Hold at CLSA
Jefferies Analyst forecast on CH:RV6
David Windley
Jefferies
Jefferies
CHF179.65
Buy
―
Reiterated
05/08/26
Analysts Offer Insights on Healthcare Companies: Plus Therapeutics (NASDAQ: PSTV) and Charles River Labs (NYSE: CRL)
Mizuho Securities Analyst forecast on CH:RV6
Ann Hynes
Mizuho Securities
Mizuho Securities
CHF139.73→CHF153.3
Hold
―
Reiterated
05/08/26
Charles River price target raised to $192 from $175 at MizuhoCharles River price target raised to $192 from $175 at Mizuho
Robert W. Baird Analyst forecast on CH:RV6
Eric Coldwell
Robert W. Baird
Robert W. Baird
CHF159.69→CHF170.07
Buy
―
Reiterated
05/08/26
Charles River price target raised to $213 from $200 at BairdCharles River price target raised to $213 from $200 at Baird
Evercore ISI Analyst forecast on CH:RV6
Elizabeth Anderson CFA
Evercore ISI
Evercore ISI
CHF159.69→CHF175.66
Buy
―
Reiterated
05/08/26
Charles River price target raised to $220 from $200 at Evercore ISICharles River price target raised to $220 from $200 at Evercore ISI
J.P. Morgan Analyst forecast on CH:RV6
Casey Woodring
J.P. Morgan
J.P. Morgan
CHF131.75→CHF127.75
Hold
―
Assigned
04/13/26
Charles River price target lowered to $160 from $165 at JPMorganCharles River price target lowered to $160 from $165 at JPMorgan
Citi Analyst forecast on CH:RV6
Patrick B Donnelly
Citi
Citi
CHF211.59
Buy
―
Reiterated
01/15/26
Analysts Offer Insights on Healthcare Companies: Charles River Labs (NYSE: CRL) and Molina Healthcare (NYSE: MOH)
Argus Research Analyst forecast on CH:RV6
David Toung
Argus Research
Argus Research
CHF159.69
Buy
―
Upgraded
11/17/25
Charles River upgraded to Buy from Hold at ArgusCharles River upgraded to Buy from Hold at Argus
Deutsche Bank Analyst forecast on CH:RV6
Justin Bowers
Deutsche Bank
Deutsche Bank
CHF143.72→CHF147.71
Buy
―
Reiterated
08/07/25
Deutsche Bank Keeps Their Buy Rating on Charles River Labs (CRL)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Charles River Labs

3 Months
David WindleyJefferies
Success Rate
25/43 ratings generated profit
58%
Average Return
+3.81%
Copying David Windley's trades and holding each position for 3 Months would result in 58.14% of your transactions generating a profit, with an average return of +3.81% per trade.
1 Year
David WindleyJefferies
Success Rate
33/43 ratings generated profit
77%
Average Return
+12.93%
Copying David Windley's trades and holding each position for 1 Year would result in 76.74% of your transactions generating a profit, with an average return of +12.93% per trade.
2 Years
David WindleyJefferies
Success Rate
33/43 ratings generated profit
77%
Average Return
+19.13%
Copying David Windley's trades and holding each position for 2 Years would result in 76.74% of your transactions generating a profit, with an average return of +19.13% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RV6 Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
0
0
0
0
Buy
22
20
11
13
19
Hold
7
5
5
3
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
29
25
16
16
23
In the current month, RV6 has received 19 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. RV6 average Analyst price target in the past 3 months is 166.40.
Each month's total comprises the sum of three months' worth of ratings.

RV6 Financial Forecast

RV6 Earnings Forecast

Next quarter’s earnings estimate for RV6 is $2.20 with a range of $2.15 to $2.34. The previous quarter’s EPS was $1.66. RV6 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year RV6 has Performed in-line its overall industry.
Next quarter’s earnings estimate for RV6 is $2.20 with a range of $2.15 to $2.34. The previous quarter’s EPS was $1.66. RV6 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year RV6 has Performed in-line its overall industry.

RV6 Sales Forecast

Next quarter’s sales forecast for RV6 is $787.13M with a range of $771.08M to $824.20M. The previous quarter’s sales results were $801.52M. RV6 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year RV6 has Performed in-line its overall industry.
Next quarter’s sales forecast for RV6 is $787.13M with a range of $771.08M to $824.20M. The previous quarter’s sales results were $801.52M. RV6 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year RV6 has Performed in-line its overall industry.

RV6 Stock Forecast FAQ

What is CH:RV6’s average 12-month price target, according to analysts?
Based on analyst ratings, Charles River Laboratories Intl’s 12-month average price target is 166.40.
    What is CH:RV6’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:RV6, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Charles River Laboratories Intl a Buy, Sell or Hold?
        Charles River Laboratories Intl has a consensus rating of Strong Buy, which is based on 10 buy ratings, 2 hold ratings and 0 sell ratings.
          What is Charles River Laboratories Intl’s share price target?
          The average share price target for Charles River Laboratories Intl is 166.40. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $187.64 ,and the lowest forecast is $127.75. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Charles River Laboratories Intl?
            Charles River Laboratories Intl’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
              How can I buy shares of Charles River Laboratories Intl?
              To buy shares of CH:RV6, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.